Intuitive Surgical, Inc. — FY 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. The filing also reports unaudited fourth-quarter results; it is not a standalone Q4 filing. Unless stated otherwise, financial amounts are in U.S. dollars.
Business context
Intuitive Surgical designs, manufactures, and sells da Vinci robotic surgical systems, instruments and accessories, and related service and training. Its revenue combines capital sales of systems with recurring sales of instruments, accessories, and service. The company operated as one reporting segment. At year-end, its installed base was 2,585 systems, and it estimated approximately 450,000 procedures were performed during 2012.
Financial results and liquidity
| Metric | FY 2012 | FY 2011 | Change |
|---|---|---|---|
| Revenue | $2,178.8 million | $1,757.3 million | +24% |
| Gross profit / margin | $1,570.3 million / 72% | $1,273.8 million / 72% | +23% gross profit |
| Operating income / margin | $878.1 million / 40% | $694.8 million / 39% | +26% |
| Net income / diluted EPS | $656.6 million / $15.98 | $495.1 million / $12.32 | +33% net income |
| Cash from operating activities | $814.2 million | $677.6 million | +20% |
| Cash, cash equivalents and investments | $2,920.5 million | $2,171.8 million | +$748.7 million |
Q4 2012 revenue was $609.3 million, gross profit $437.9 million, net income $174.9 million, and diluted EPS $4.25. In Q4 2011, the respective figures were $496.8 million, $362.9 million, $151.2 million, and $3.75.
Recurring revenue rose 27% to $1,245.9 million and represented 57% of total revenue, versus 56% in 2011. Systems revenue increased 20% to $932.9 million on 620 system sales, compared with 534 in 2011; instruments and accessories revenue increased 29% to $903.3 million. Product gross margin eased to 73.0% from 74.1%, primarily due to lower initial margins on newly introduced products. Service gross margin improved to 67.0% from 63.7%.
Year-end current assets were $1,892.8 million and current liabilities $401.6 million. Total liabilities were $479.1 million and shareholders’ equity $3,580.1 million. The balance sheet reports no interest-bearing debt balance. Cash from operations was the principal source of liquidity; investing activities used $845.7 million, including net investment purchases and $141.8 million for property, equipment, intellectual property, and business purchases. Financing activities provided $119.2 million, including stock issuance proceeds, partly offset by $238.3 million of share repurchases. Management said current cash and investment balances and expected operating cash flows should meet liquidity needs for the foreseeable future.
Material changes and operating trends
- Estimated procedure volume increased approximately 25% year over year. U.S. procedures rose to approximately 367,000 from 292,000; international procedures rose to approximately 83,000 from 68,000.
- U.S. gynecologic procedures, including hysterectomies, and general surgery drove growth. U.S. prostatectomy procedures declined approximately 15%, to about 62,000, amid lower PSA testing and greater use of non-surgical management.
- International revenue increased to $451.9 million, or 21% of total revenue, from $378.6 million, or 22%. European procedure growth was weaker than expected amid austerity and other market pressures.
- Operating expenses increased 20% to $692.2 million, including a 19% increase in selling, general and administrative expenses and a 21% increase in R&D. Headcount grew to 2,362 from 1,924.
- The effective tax rate declined to approximately 26.5% from 30.2%. FY 2012 included $46.5 million in discrete tax benefits; the federal R&D tax credit was not included in the 2012 provision and was retroactively extended in January 2013.
Outlook, risks, and unusual items
- The filing gives no numerical revenue or earnings guidance. Management expected R&D spending to continue increasing and recurring revenue to become a larger share of revenue.
- The 2.3% U.S. medical-device excise tax took effect in 2013. Management estimated the impact at approximately 1% of total global revenue, with the tax treated as a cost of revenue.
- Key risks include adoption and reimbursement uncertainty, hospital capital-spending constraints, competition, procedure trends, regulatory clearances, product quality and liability, manufacturing capacity, and dependence on sole- or single-source suppliers. Foreign exchange exposure and economic weakness, particularly in Europe, also pose risks.
- A securities class action dismissed with prejudice in 2012 remained on appeal; related derivative actions were stayed pending that appeal. The company had not accrued amounts for these matters, citing uncertainty over outcome and inability to estimate losses. Management considered a material adverse outcome unlikely based on available information.
- The company held $7.4 million of illiquid auction-rate securities backed by student loans; auctions had continued to fail. It warned of possible further valuation losses, although no significant investment impairment charges were recorded for 2010–2012.
- Purchase commitments and obligations totaled $292.2 million, primarily ordinary-course supplier and purchase orders, many of which were cancellable or adjustable. Total contractual obligations were $300.7 million. No significant off-balance-sheet arrangements were reported.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The filing reports effective disclosure controls and internal controls as of year-end.
Important facts for investors to verify
- Whether procedure growth and recurring revenue can offset continued weakness in U.S. prostatectomy procedures and slower European growth.
- Adoption, economics, and regulatory expansion of newer products, including Single-Site, the vessel sealer, and the Stapler 45; the Stapler rollout was planned for 2013.
- The effect of the 2013 medical-device excise tax, reimbursement changes, and any associated impact on hospital purchasing or procedure volumes.
- The status and potential financial effect of the securities-litigation appeal, related derivative actions, and product-liability claims or solicitations.
- Cash-flow conversion and investment liquidity, including the valuation and recovery prospects of the auction-rate securities.